**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following a December 2025 executive order directing expedited action.** The broader rulemaking for all marijuana forms advanced to an administrative hearing that ran from June 29 to mid-July 2026, with selected participants largely opposing the change and some pro-rescheduling parties excluded. Post-hearing, the DEA and Department of Justice must complete the formal rulemaking process, which includes potential further review, public comments, and possible legal challenges before a final rule takes effect. These procedural steps, combined with the hearing's limited participant pool and historical timelines for Controlled Substances Act amendments, have kept trader-implied probabilities for full rescheduling by year-end in the low-to-mid 20s percent range. Key upcoming milestones include the DEA's post-hearing determination and any subsequent Federal Register actions that could accelerate or extend the timeline.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড$796,329 Vol.
Mar 31, 2026
September 30
14%
December 31
29%
$796,329 Vol.
September 30
$0 Vol.
14%
December 31
$186,758 Vol.
29%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following a December 2025 executive order directing expedited action.** The broader rulemaking for all marijuana forms advanced to an administrative hearing that ran from June 29 to mid-July 2026, with selected participants largely opposing the change and some pro-rescheduling parties excluded. Post-hearing, the DEA and Department of Justice must complete the formal rulemaking process, which includes potential further review, public comments, and possible legal challenges before a final rule takes effect. These procedural steps, combined with the hearing's limited participant pool and historical timelines for Controlled Substances Act amendments, have kept trader-implied probabilities for full rescheduling by year-end in the low-to-mid 20s percent range. Key upcoming milestones include the DEA's post-hearing determination and any subsequent Federal Register actions that could accelerate or extend the timeline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Feb 7, 2026, 5:04 PM ET
ভলিউম
$796,329শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following a December 2025 executive order directing expedited action.** The broader rulemaking for all marijuana forms advanced to an administrative hearing that ran from June 29 to mid-July 2026, with selected participants largely opposing the change and some pro-rescheduling parties excluded. Post-hearing, the DEA and Department of Justice must complete the formal rulemaking process, which includes potential further review, public comments, and possible legal challenges before a final rule takes effect. These procedural steps, combined with the hearing's limited participant pool and historical timelines for Controlled Substances Act amendments, have kept trader-implied probabilities for full rescheduling by year-end in the low-to-mid 20s percent range. Key upcoming milestones include the DEA's post-hearing determination and any subsequent Federal Register actions that could accelerate or extend the timeline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ভলিউম
$796,329শেষ তারিখ
Mar 31, 2026মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of certain marijuana products to Schedule III occurred in April 2026 via Acting Attorney General order, following a December 2025 executive order directing expedited action.** The broader rulemaking for all marijuana forms advanced to an administrative hearing that ran from June 29 to mid-July 2026, with selected participants largely opposing the change and some pro-rescheduling parties excluded. Post-hearing, the DEA and Department of Justice must complete the formal rulemaking process, which includes potential further review, public comments, and possible legal challenges before a final rule takes effect. These procedural steps, combined with the hearing's limited participant pool and historical timelines for Controlled Substances Act amendments, have kept trader-implied probabilities for full rescheduling by year-end in the low-to-mid 20s percent range. Key upcoming milestones include the DEA's post-hearing determination and any subsequent Federal Register actions that could accelerate or extend the timeline.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা